Filed by former Parke-Davis employee David Franklin, this lawsuit alleged that the company violated federal regulations by engaging in systematic efforts to promote the anti-seizure drug gabapentin (Neurontin) for uses not approved by the US Food and Drug Administration. The case was concluded in May 2004 with a $430 million settlement and an agreement by Parke-Davis to plead guilty to resolve civil liabilities and criminal charges pertaining to the case.
Browse Franklin v Park-Davis documents
Consumers and third-party payers, including insurance companies and trade unions, sought repayment of billions of dollars paid for Neurontin prescriptions alleging Pfizer fraudulently misrepresented the drug's benefits. The plaintiffs argued the documents in this case revealed that even after the Neurontin settlement (see Franklin v Parke-Davis above), Pfizer "continued with the medical marketing firms and planted marketing messages in journal articles (saying) that Neurontin was effective while they knew that their own clinical trials had failed to demonstrate it was effective."
Browse Neurontin Marketing and Sales Practices Litigation documents